SOLICITATION NOTICE
Q -- Autism Sequencing Project
- Notice Date
- 8/5/2010
- Notice Type
- Presolicitation
- NAICS
- 813319
— Other Social Advocacy Organizations
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Heart, Lung and Blood Institute, Rockledge Dr. Bethesda, MD, Office of Acquisitions, 6701 Rockledge Dr RKL2/6100 MSC 7902, Bethesda, Maryland, 20892-7902
- ZIP Code
- 20892-7902
- Solicitation Number
- NHLBI-PB-(HG)-2010-268-DLM
- Archive Date
- 8/26/2010
- Point of Contact
- Dorothy Maxwell, Phone: 301-435-0352
- E-Mail Address
-
maxwelld@mail.nih.gov
(maxwelld@mail.nih.gov)
- Small Business Set-Aside
- N/A
- Description
- THIS IS A NOTICE OF INTENT, NOT A REQUEST FOR A PROPOSAL. A SOLICITATION DOCUMENT WILL NOT BE ISSUED AND PROPOSALS WILL NOT BE REQUESTED. The National Heart, Lung, and Blood Institute (NHLBI) Office of Acquisition (OA) intends to negotiate and award a purchase order on a noncompetitive sole source basis to Autism Genetic Resource Exchange, Autism Speaks, 5455 Wilshire Boulevard, Suite 2250, Los Angeles, California 90036-4279 to procure Cell Line and Plasma Samples. The sole source determination is based on the fact that National Institute of Health (NIH) is the nation’s medical research agency and the primary Federal agency conducting and supporting making medical discoveries that improve people’s health and save lives. The National Human Genome Research Institute (NHGRI) in collaboration with an investigator from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) is currently studying patients with autism/autism spectrum disorder (ASD) and their families. The purpose of both these studies is to detect, localize and characterize genes that increase risk for this complex disease. The study is focusing on ASD patients with either hypo-cholesterolemia or hyper-cholesterolemia. This study has approval from the NICHD Institutional Review Board (IRB). As part of this study, plasma samples are needed from a set of ASD patients with a family history of a close relative who also has autism and who have previously deposited blood, plasma, and cell line samples in the Autism Genetic Resource Exchange (AGRE) sample repository, specifically for use in genetic studies. NIH has obtained research approval from AGRE and from their parent organization, Autism Speaks, for use of these unique specimens in a whole exome sequencing study. As part of this study, we have already performed sterol analysis of some ASD patients (in previously obtained plasma samples) and now must perform lipoprotein analyses on 188 plasma samples from patients from families with multiple ASD patients to determine whether they have abnormal lipoprotein levels. This is a sole source purchase of aliquots of these unique and valuable samples because this is an ongoing study of these families, this is the only family registry of multiplex ASD families that we have access to and we cannot obtain samples from large numbers multiplex families from other sources. The period of performance is for 12 months. STATEMENT OF WORK Purpose and Objectives: (1) Plasma samples for lipoprotein analysis: As part of this study, we have already performed sterol analysis of some ASD patients (in previously obtained plasma samples) and now must perform lipoprotein analyses on 188 plasma samples from patients from families with multiple ASD patients to determine whether they have abnormal lipoprotein levels. Plasma samples will be aliquoted from the AGRE sample repository and shipped under appropriate conditions to NIH for analysis. (2) Plasma samples for sterol analysis: As part of this study, we have already performed sterol analysis of some ASD patients (in previously obtained plasma samples) and now need to perform sterol testing on 353 plasma samples from additional ASD patients and family members in families with multiple ASD patients to determine cholesterol levels. Plasma samples will be aliquoted from the AGRE sample repository and shipped under appropriate conditions to NIH for Analysis. (3) Cell line samples for DNA sequencing and genotyping analysis: As part of this study, we have previously obtained cell lines from some of the AGRE ASD patients and family members but now need to obtain 293 DNA samples (from cell lines) from additional patients and family members in families with multiple ASD patients. Cell line samples will be aliquoted from the AGRE sample repository and shipped under appropriate conditions to NIH for Analysis. (4) Recontact for reconsent of ASD study participants for whole exome/whole genome sequencing study: The Contractor will mail brochures and consent forms to a subset of the AGRE registry participating families (92 families), with follow-up telephone calls, to facilitate the reconsent process for our proposed DNA sequencing study. Contractor Requirements: (1) The Contractor will ship 188 plasma sample aliquots in appropriate shipping containers (to maintain correct temperature and security of specimens during shipping) to NIH. (2) The Contractor will ship 353 plasma sample aliquots in appropriate shipping containers (to maintain correct temperature and security of specimens during shipping) to NIH. (3) The Contractor will ship 293 cell line sample aliquots in appropriate shipping containers (to maintain correct temperature and security of specimens during shipping) to NIH. (4) The Contractor will mail brochures and consent forms to a subset of the AGRE registry participating families, with follow-up telephone calls, to facilitate the reconsent process for our proposed DNA sequencing study. Industry Classification (NAICS) Code is 813319, Other Social Advocacy Organizations, with size standard in dollars $7.0M Per Annum. The acquisition is being conducted under FAR Part 13, simplified acquisition procedures, therefore the requirements of FAR Part 6 B Competitive Requirements are not applicable (FAR Part 6.001) and the resultant purchase order will include all applicable provisions and clauses in effect through the Federal Acquisition Circular (FAC) 05-43 (July 23, 2010). This notice of intent is not a request for competitive proposals. Interested parties may identify their interest and capabilities in response to this synopsis, by August 11, 2010, 7:30 a.m. Eastern Standard Time. The determination by the Government not to compete the proposed contract based upon responses to this notice is solely within the discretion of the Government. Information received will normally be considered solely for the purpose of determining whether to conduct future competitive procurement. Inquires to this announcement, referencing synopsis number NHLBI-PB-(HG)-2010-268-DLM, may be submitted to the National Heart, Lung and Blood Institute, Office of Acquisition, Procurement Branch, 6701 Rockledge Drive, Suite 6149, Bethesda, Maryland 20892-7902, Attention: Dorothy Maxwell. Response may be submitted electronically to maxwelld@mail.nih.gov. Faxes will not be accepted. Responses will only be accepted if dated and signed by an authorized company representative.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/NHLBI/NHLBI-PB-(HG)-2010-268-DLM/listing.html)
- Place of Performance
- Address: NIH, Bethesda, Maryland, 20892, United States
- Zip Code: 20892
- Zip Code: 20892
- Record
- SN02230134-W 20100807/100805235333-a5c5751b4ac248d552bff23bb26d52d6 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |